Conference Day One | Wednesday, June 4
7:30 am Check-In & Coffee
8:30 am Chair Opening Remarks
8:40 am Industry leaderβs Fireside Chat: Navigating the Path to the Clinic to Accelerate Clinical Efficacy
Synopsis
- Discussing preclinical development best practices to supercharge preclinical approval
- Discussing translational and IND approval challenges
- Highlighting clinical successes
9:30 am Keynote Presentation: Unveiling Transformative IND Data to Supercharge the Clinical Progression of In Vivo Cell Engineering & Gene Editing Therapies
Synopsis
- Showcasing IND application data to streamline the IND approval process
- Evaluating outcomes and identifying key learnings to efficiently and effectively enhance the next wave of clinical progression
10:00 am Morning Break & Speed Networking
Synopsis
As this community reunites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.Β
11:00 am Keynote Presentation: Highlighting Myeloidβs Groundbreaking Clinical Experience with the First In Vivo CARs Applied to Humans
Synopsis
- Exploring CAR designs to target myeloid, NK, and T cells to enhance therapeutic precision when combating solid tumorsΒ
- Leveraging LNP technology to create a scalable, accessible, cost-effective platformΒ
- Uncovering first-in-class phase 1 clinical trial data, demonstrating safety promising clinical benefitsΒ
11:30 am Elevating Clinical Trial Design to Improve Trial Outcomes & Supercharge Treatment Approval
Synopsis
- Evaluating clinical trial designs to accelerate treatment progression and approval
- Leveraging key insights on patient population and data collection to boost clinical trial success
- Identifying unforeseen challenges in clinical trial development and execution to improve outcomes
12:00 pm Roundtable Discussion: Navigating Clinical Trial Design, Including Treatment Indication & Patient Eligibility
Synopsis
- Discussing key considerations when selecting appropriate treatment indications
- Identifying patient eligibility criteria and endpoints to ensure safe, reliable and actionable clinical data
- Exploring strategies for determining the optimal patient population for viral and non-viral delivery methods
12:45 pm Lunch Break & Networking
1:45 pm Enabling High Precision In Vivo CAR-T Therapy with Targeted Fusogens
Synopsis
- Comparing methods of cell specific in vivo CAR-T generation.
- Enabling high precision cell-specific gene editing with Sanaβs Fusogen platform, which mediates cell entry via a mechanism that directly couples receptor recognition to cell entry, in contrast to endosomal escape delivery systems.
- Developing a T cell-specific Fusogen to enable in vivo CAR-T therapy, including in vivo data showing potent and cell-specific CAR-T generation and robust B cell depletion in animal models.
2:15 pm Exploring Treatment Engineering Approaches to Overcome Off-Target Toxicity
Synopsis
- Analyzing the antibody approach to targeting and discussing immunogenicity and toxicity produced by antibody conjugation
- Investigating alternative strategies to enhance targeting and improve safety profiles without antibody conjugation
- Presenting Cytodigmβs novel approach to target extrahepatic tissues and cell while reducing off-target toxicity
2:45 pm Roundtable Discussion: Overcoming Treatment Uptake by the Liver to Enhance Delivery Efficiency & Prevent Hepatotoxicity
Synopsis
- Exploring surface binders as a strategy to de-target the liver and enhance precision
- Reimagining vehicle design to de-target the liver, improving treatment uptake and delivery efficiency
- Developing strategies to detoxify the liver to prevent hepatotoxicity and improve patient outcomes
3:30 pm Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.
4:00 pm Translating & Harnessing Key Learnings from Ex Vivo Therapies to Supercharge In Vivo Clinical Progression
Synopsis
- Reviewing the translational capacity of current preclinical models to highlight required improvements in model type and size
- Identifying suitable animal models based on specific therapeutic indications and desired outcomes to produce reliable, translational results and accelerate clinical progression
- Showcasing the evolution from ex vivo to in vivo CAR Therapies
4:30 pm Investigating Strategies to Refine Translational Outcomes & Direct Future Advancements
Synopsis
- Discussing strategies to effectively triangulate preclinical models to decrease the variability of translational outcomes
- Showcasing accurate translational data utilizing methods triangulating preclinical models
- Exploring future advancements in preclinical models to further enhance translational precisionΒ